Overview

Clearing Lungs With Epithelial Sodium Channel (ENaC) Inhibition in Cystic Fibrosis (CF)

Status:
Completed
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
The goal of the study is to evaluate the safety and tolerability of P-1037 and to determine whether the combination of P-1037 with hypertonic saline or P-1037 alone has a greater effect on lung function in patients with CF than placebo (0.17% saline).
Phase:
Phase 2
Details
Lead Sponsor:
Parion Sciences
Vertex Pharmaceuticals Incorporated
Collaborators:
Parion Sciences
Vertex Pharmaceuticals Incorporated
Treatments:
Pharmaceutical Solutions